GlassScriptPhysician profile
David B Sumerford
NPI 1508193459
$2,847.40
in general payments reported to CMS, 2019-2025
17 companies · $489 in 2025
The $489 reported for 2025 was more than what a typical Psychiatric/Mental Health (Nurse Practitioner) provider received nationally (typical 2025 total: $257).
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $554 · 2022: $720 · 2023: $576 · 2024: $508 · 2025: $489.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,574.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,573.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $957.10 | 2021-2025 | Caplyta |
| Abbvie INC. | $604.28 | 2021-2025 | |
| Janssen Pharmaceuticals, INC | $337.46 | 2021-2025 | Spravato, Invega Sustenna |
| Otsuka America Pharmaceutical, INC. | $234.12 | 2021-2024 | Rexulti, Abilify Maintena, Nuedexta |
| Takeda Pharmaceuticals U.S.A., INC. | $199.72 | 2021-2025 | Trintellix |
| Alkermes, INC. | $114.90 | 2021-2022 | |
| Teva Pharmaceuticals USA, INC. | $89.32 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $75.80 | 2025 | Cobenfy |
| Supernus Pharmaceuticals, INC. | $58.12 | 2025 | Qelbree |
| Bausch Health US, LLC | $30.50 | 2021 | |
| Vanda Pharmaceuticals INC. | $29.46 | 2024 | Hetlioz, Fanapt |
| Axsome Therapeutics, INC. | $27.55 | 2024 | Auvelity |
| Radius Health, INC. | $27.25 | 2023 | Tymlos |
| Modernatx, INC. | $19.33 | 2023 | Moderna Covid-19 Vaccine |
| Avanir Pharmaceuticals, INC. | $16.94 | 2021 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Adlon Therapeutics L.P. | $13.09 | 2021 | |
| Neuronetics, INC. | $12.46 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Sumerford listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.